Home > Boards > Free Zone > Health and Sciences > Biotech Values

Re: <u>Interpreting ABBV/ENTA&rsquo;s SAPHIRE-1 results</u>

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 754
Posts 116,260
Boards Moderated 10
Alias Born 09/05/02
160x600 placeholder
Truist Financial Raises Quarterly Cash Dividend
Truist Financial Corp. on Tuesday said its board raised the company's regular quarterly cash dividend by 7%.
Mondelez: Currency Translations to Boost Full-Year Revenue Growth -- Currency Comment
Visa Profit, Net Revenue Climbs with Payments Volume Increasing
Mondelez Raises Fiscal Year Organic Net Revenue Growth Outlook
U.S. Crude-Oil Stockpiles Likely to Fall in DOE Data, Analysts Say -- Update
Top Company News of the Day
Stryker Swings to 2Q Profit as Pandemic Moderated
Starbucks Says Foreign Exchange Rates Boosted 3Q Revenue -- Currency Comment
AMD Raises Revenue Guidance Following Better-than-Expected 2Q Performance
Mondelez 2Q Profit Nearly Doubles As Sales Rise on Consumer Demand
ObsEva Shares Climb 10% on Licensing Deal With Organon
Wheat Slides as Traders Take Tentative Stance -- Daily Grain Highlights
Front Month Nymex RBOB Gasoline Rose 0.25% to Settle at $2.3141 -- Data Talk
Front Month Nymex Natural Gas Fell 3.19% to Settle at $3.9710 -- Data Talk
Boston Scientific Third Best Performer in the S&P 500 So Far Today -- Data Talk
Shell New Energies to Buy Inspire Energy Capital
Yum China Down Over 6%, on Pace for Largest Percent Decrease Since May 2020 -- Data Talk
Rio Tinto Commits $2.4 Billion to Serbian Lithium Project
Europcar Confirms Advanced Takeover Talks With Volkswagen Consortium
Rio Tinto Commits $2.4 Billion to Lithium Project in Serbia -- Commodity Comment
Casino, Credit Mutuel to Sell Payment Provider to BNP Paribas for EUR258 Million
DewDiligence Member Level  Monday, 11/18/13 10:11:46 AM
Re: ronpopeil post# 170103
Post # of 238823 
Re: Interpreting ABBV/ENTA’s SAPHIRE-1 results

98% SVR12 in GT1b and 95% SVR12 in GT1a—both on an ITT basis—are excellent efficacy results, of course. However, SAPHIRE-1 (and the yet-to-report SAPHIRE-2) are primarily safety studies, as noted in #msg-91739317.

How did the 3-DAA+ribavirin arm perform in SAPHIRE-1 relative to the placebo arm on safety? From today’s PR:
Quote:
The most commonly reported adverse events in the 3D and placebo arms, respectively, were fatigue, headache and nausea. Discontinuations due to adverse events were reported in 0.6 percent of patients receiving the 3D regimen and 0.6 percent of patients receiving placebo.

In other words, there were no excess dropouts in the treatment arm relative to the placebo arm, which is as good an outcome as one could hope for (pending the detailed data on AEs to be presented at a medical conference).

All told, SAPHIRE-1 looks like an excellent start to ABBV/ENTA’s array of six phase-3 trials for the initial NDA submission in 2Q14. The five other phase-3 trials to support the initial NDA are SAPHIRE-2, PEARL-2/3/4, and TURQUOISE-2, as detailed in #msg-93647264.


Background on SAPHIRE-1: The “placebo” arm in SAPHIRE-1 was actually a delayed treatment arm insofar as patients received the same regimen as the treatment arm, but the start of treatment was delayed by 12 weeks in order to make a safety comparison between the arms. HCV progresses much too slowly for a 12-week delay to affect the efficacy results in the delayed-treatment arm (which have yet to be reported).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences